{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Maximum Tolerated Dose (MTD) reflects the highest dose of Veliparib when combined with Bendamustine Hydrochloride that did not cause a DLT. The maximum tolerated dose (MTD) was defined as the highest dose level at which 33% of patients experienced DLT.","groups":[{"description":"All Study Participants","id":"OG000","title":"All Study Participants"}],"paramType":"NUMBER","populationDescription":"The MTD was established at Dose Level 6 Veliparib 300mg PO BID plus Bendamustine 90 mg/m2","reportingStatus":"POSTED","timeFrame":"28 days","title":"Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride","type":"PRIMARY","unitOfMeasure":"mg"}